Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen.
Drugs that act on it: 8
Approved: 4
In phases 1 to 3: 4
Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on PLAT, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Small molecule 1
Protein or peptide 7
Approved4
AlteplaseAlteplaseSponsorRocheModalityProtein or peptideActionExogenous proteinOpen trials105
TenecteplaseTenecteplaseSponsorRocheModalityProtein or peptideActionExogenous proteinOpen trials82
ReteplaseReteplaseSponsorEKR TherapeuticsModalityProtein or peptideActionExogenous proteinOpen trials6
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Tissue-type plasminogen activator exogenous protein; the rest name their own mechanism.
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1873, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00750, CC BY 4.0) and disease associations are from Open Targets (CC0).ChEMBL and Open Targets
Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.